This feature could explain the resistance (primary or secondary) to anti-VEGF drugs that has long been reported in RCC, BC and PMF patients and highlights the urgency of identifying novel targets to interfere with angiogenesis in cancer patients [283,312]. Here, VEGFA is linked to cancer.